Abstract 283P
Background
Worldwide, there are approximately 560 000 new cases diagnosed with head and neck cancer and 300 000 deaths each year. In developing countries including Sub-Saharan Africa, head and neck cancer is rare compared to other cancers. The aims of this study are to estimate the incidence and determine the epidemiological characteristics of head and neck cancer in the population of Niger.
Methods
This is a descriptive retrospective study of head and neck cancer cases, reported to the Niger Cancer Registry in the period 1992-2009. Head and neck cancer includes the following: lip, tongue, mouth (floor, palate and other), salivary glands, tonsils, pharynx (oro-, naso- and hypopharynx), larynx, nose, ear, head and neck not otherwise specified.
Results
In 1992-2009, there were 344 cases diagnosed with head and neck cancer in Niger, which was 4.89% of all cases of cancer reported during this period, with a male-female ratio of 1.49. The incidence rate of head and neck cancer was 2.34 cases per 100 000 persons. Oral cancer was the most common cancer (27.6%), followed by laryngeal and salivary glands cancers (13.1%) and tonsil cancer (10.2%). The mean age at diagnosis of the patients was 42.11±18.24 years. The commonest histological type was squamous cell carcinoma in 27.1% of cases. We registered 11 deaths, with a fatality rate of 3.19%.
Conclusions
Although the incidence rates for head and neck cancers are lower, these cancers include a diverse group of uncommon tumors that frequently are aggressive. Because of the seriousness of cancer in Niger; the health authorities should pay more attention to this pathology through efficient fight strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session